Results 201 to 210 of about 415,375 (309)

Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson's disease. [PDF]

Front Pharmacol
Lv J, Fu H, Zhou Y, Li W, Zhang J, Zhou Z, Lai S.   +6 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Trends in the Use of a Financial Incentive for Device-assisted Rehabilitation in Japan: A Descriptive Analysis Using National Health Insurance Data. [PDF]

Prog Rehabil Med
Kubo D, Hirose T, Asaoka Y.
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source

Rehabilitation Perspectives in Unilateral Upper Limb Peromelia: A Case Report. [PDF]

Cureus
S K, Sujatha G, Pathak S.
europepmc   +1 more source

Virtual reality mediated brain-computer interface training improves sensorimotor neuromodulation in unimpaired and post spinal cord injury individuals. [PDF]

Sci Rep
Mannan MMN, Palipana DB, Mulholland K, Jurd E, Lloyd ECR, Quinn ARJ, Crossley CB, Rabbi MF, Lloyd DG, Teng YD, Pizzolato C.   +10 more
europepmc   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Vagus Nerve Stimulation Paired With Upper Extremity Rehabilitation for Chronic Stroke: Real-World Implementation and Outcomes. [PDF]

Arch Rehabil Res Clin Transl
Saylor A, Patrick L, Reddy CG, Gandhi R.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Impact of motor anxiety on rehabilitation in elderly stroke patients: A retrospective study. [PDF]

World J Psychiatry
Yang YB, Tang LP, Yu CY, Fu CL, Yang JP.
europepmc   +1 more source